ClearPoint Neuro, Inc. (CLPT) shares surged 26% to close at $16.81 during the last trading session. This significant gain follows investor optimism regarding a regulatory milestone announced by partner company uniQure N.V. for its Huntington’s disease treatment candidate, AMT-130, which may lead to accelerated approval by the FDA based on a Phase I/II study’s three-year analysis.
ClearPoint is expected to report a quarterly loss of $0.27 per share, reflecting a 28.6% year-over-year decrease, while revenues are projected to reach $13 million, marking a 41% increase from the previous year. The company’s recent stock performance follows a 19.4% increase over the past month and remains under Zacks Rank #3 (Hold).
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
